Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

• Status: Completed
• Trial end date: 2006-10-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine the safety and efficacy of elsamitrucin in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). To determine if elsamitrucin is efficacious in a particular pathologic NHL subtype(s).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Spectrum Pharmaceuticals, Inc
• Treatments: Elsamicin A

Criteria

Inclusion Criteria:

• Relapsed or Refractory mantle cell lymphoma and/or CLL/SLL except Burkitt's, Burkitt's like or HIV-associated lymphoma

• at least one prior cytotoxic chemotherapy regimens

• measurable disease

• adequate bone marrow, liver and kidney function

• ECOG PS 0-2

Exclusion Criteria:

• prior treatment with elsamitrucin

• prior chemo, antibody or radiotherapy for NHL within 28 days prior to start to treatment

• HIV positive or known AIDS syndrome

• uncontrolled medical disease or psychiatric condition/s